FDA to allow generics makers to change labelling

Home/Policies & Legislation | Posted 22/11/2013 post-comment0 Post your comment

On 8 November 2013 the US Food and Drug Administration (FDA) announced that it had published its proposed rule allowing generics makers to change their labelling in the Federal Register.

picture 86

The new rule intends to speed the dissemination of new safety information about generics to healthcare professionals and patients by allowing generics makers to use the same process as brand-name drug manufacturers to update safety information in the product labelling.

Generics account for over 80% of prescription drugs dispensed to American patients. But under current regulations generics manufacturers cannot update the labelling of their products until the brand-name manufacturer does so. They can only provide supporting information to FDA, which then determines whether safety information for both the brand-name and generic drugs should be revised before updates can occur.

The new rule being proposed by FDA would allow generics manufacturers to independently update and promptly distribute revised product labelling – in the same way as brand-name manufacturers already do – before FDA reviews or approves the change. Generics manufacturers would also be required to inform the brand-name manufacturer about the change so that they could also consider the information provided by the generics manufacturer as part of its review and evaluation of adverse drug experience information for its drug.

The proposed rule has been welcomed by patient advocacy groups, but has been met with concern from generics groups. Patient Advocacy group Public Citizen, which has been petitioning FDA on generics labelling, was pleased with the FDA announcement, saying that ‘the rule will provide added protection to the tens of millions of people who regularly use generic drugs’. The Generic Pharmaceutical Association (GPhA), which represents generics manufacturers in the US, on the other hand, said that it ‘is very concerned that multiple versions of critical safety information would lead to unnecessary confusion and uncertainty for prescribers and other healthcare professionals, with harmful consequences for patients.’

The proposed rule could also open up generics companies to liability over product labelling. They had previously been protected from such claims by US Supreme Court rulings made in 2011 and 2013. These stated that generics makers were pre-empted by federal law from being sued for failing to provide adequate label warnings about potential side effects [1] and that generics makers could not be sued by patients for injuries, due to the fact that generics manufacturers either need FDA to order a label change or the brand-name manufacturer to do it first [2].

To enhance transparency while FDA is reviewing any changes, and to make safety-related changes to drug labelling quickly available to healthcare professionals and the public, FDA plans to create a web page where safety-related changes proposed by all drug manufacturers would be posted. Members of the public would also be able to subscribe to the web page to receive updates.

FDA is seeking public comment on the proposed rule, which should be submitted to FDA by 13 January 2014.

Related articles

Brand-name and generics labels don’t match

Generic pre-emption raises its ugly head again


1.  GaBI Online - Generics and Biosimilars Initiative. Generics manufacturers do not have to change drug safety labels in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 22]. Available from: www.gabionline.net/Generics/News/Generics-manufacturers-do-not-have-to-change-drug-safety-labels-in-the-US

2.  GaBI Online - Generics and Biosimilars Initiative. Generics may be allowed to change drug labelling [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 22]. Available from: www.gabionline.net/Policies-Legislation/Generics-may-be-allowed-to-change-drug-labelling

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: FDA, FDA Voice, Federal Register,GPhA, Public Citizen

comment icon Comments (0)
Post your comment
Related content
FDA publishes final Q&A on biosimilar development and the BPCI Act
Home/Policies & Legislation Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
Home/Policies & Legislation Posted 08/10/2021
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010